139 related articles for article (PubMed ID: 15536334)
1. Focal adhesion kinase overexpression in endometrial neoplasia.
Livasy CA; Moore D; Cance WG; Lininger RA
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):342-5. PubMed ID: 15536334
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Lightfoot HM; Lark A; Livasy CA; Moore DT; Cowan D; Dressler L; Craven RJ; Cance WG
Breast Cancer Res Treat; 2004 Nov; 88(2):109-16. PubMed ID: 15564794
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
Zhou J; Roh JW; Bandyopadhyay S; Chen Z; Munkarah AR; Hussein Y; Alosh B; Jazaerly T; Hayek K; Semaan A; Sood AK; Ali-Fehmi R
Gynecol Oncol; 2013 Feb; 128(2):344-8. PubMed ID: 22871469
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the focal adhesion kinase (p125FAK) in the vascular smooth muscle cells of intimal hyperplasia.
Owens LV; Xu L; Marston WA; Yang X; Farber MA; Iacocca MV; Cance WG; Keagy BA
J Vasc Surg; 2001 Aug; 34(2):344-9. PubMed ID: 11496289
[TBL] [Abstract][Full Text] [Related]
6. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Lark AL; Livasy CA; Calvo B; Caskey L; Moore DT; Yang X; Cance WG
Clin Cancer Res; 2003 Jan; 9(1):215-22. PubMed ID: 12538472
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase (FAK) involvement in human endometrial remodeling during the menstrual cycle.
Orazizadeh M; Rashidi I; Saremi J; Latifi M
Iran Biomed J; 2009 Apr; 13(2):95-101. PubMed ID: 19471549
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.
Judson PL; He X; Cance WG; Van Le L
Cancer; 1999 Oct; 86(8):1551-6. PubMed ID: 10526262
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.
Nykopp TK; Rilla K; Tammi MI; Tammi RH; Sironen R; Hämäläinen K; Kosma VM; Heinonen S; Anttila M
BMC Cancer; 2010 Sep; 10():512. PubMed ID: 20875124
[TBL] [Abstract][Full Text] [Related]
11. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
12. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Aronsohn MS; Brown HM; Hauptman G; Kornberg LJ
Laryngoscope; 2003 Nov; 113(11):1944-8. PubMed ID: 14603053
[TBL] [Abstract][Full Text] [Related]
13. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
15. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
16. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression.
Bing L; Hong C; Li-Xin S; Wei G
Arch Gynecol Obstet; 2014 Sep; 290(3):533-41. PubMed ID: 24699721
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
19. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
20. Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Zhang SQ; Cai B; Liu L; He YY; Yang YX; Wan XP
Int J Gynecol Cancer; 2009 Nov; 19(8):1377-83. PubMed ID: 20009893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
